# A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

> **NCT02906020** · PHASE2 · TERMINATED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 273 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** venglustat GZ/SAR402671
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02906020
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12-15
- **Primary completion:** 2020-12-18
- **Final completion:** 2021-05-27
- **Target enrollment:** 273 (ACTUAL)
- **Why stopped:** The topline results of the 52-week double-blind placebo-controlled period were analyzed. The study did not meet the primary or secondary endpoints. Based on these results, the decision was made to halt the long-term follow-up period of the study
- **Last updated:** 2022-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02906020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02906020, "A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02906020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*